Title : Can 18F-FDG PET/CT predict EGFR status in patients with non-small cell lung cancer? A systematic review and meta-analysis.

Pub. Date : 2021 Jun 8

PMID : 34103313






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Can 18F-FDG PET/CT predict EGFR status in patients with non-small cell lung cancer? Fluorodeoxyglucose F18 epidermal growth factor receptor Homo sapiens
2 OBJECTIVES: This study aimed to explore the diagnostic significance of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/CT for predicting the presence of epidermal growth factor receptor (EGFR) mutations in patients with non-small cell lung cancer (NSCLC). Fluorodeoxyglucose F18 epidermal growth factor receptor Homo sapiens
3 OBJECTIVES: This study aimed to explore the diagnostic significance of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/CT for predicting the presence of epidermal growth factor receptor (EGFR) mutations in patients with non-small cell lung cancer (NSCLC). Fluorodeoxyglucose F18 epidermal growth factor receptor Homo sapiens
4 OBJECTIVES: This study aimed to explore the diagnostic significance of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/CT for predicting the presence of epidermal growth factor receptor (EGFR) mutations in patients with non-small cell lung cancer (NSCLC). Fluorodeoxyglucose F18 epidermal growth factor receptor Homo sapiens
5 OBJECTIVES: This study aimed to explore the diagnostic significance of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/CT for predicting the presence of epidermal growth factor receptor (EGFR) mutations in patients with non-small cell lung cancer (NSCLC). Fluorodeoxyglucose F18 epidermal growth factor receptor Homo sapiens